The downgrade from Outperform to Market Perform and the reduction in price target from $30 to $17 by SVB Leerink analyst Thomas Smith indicates a less optimistic outlook for VectivBio Holding. This could lead to a negative short-term impact on the stock price as investors may adjust their positions based on the new rating and price target.